Troxerutin, also known as vitamin P4, is a tri-hydroxyethylated derivative of natural bioflavonoid rutins which can inhibit the production of reactive oxygen species (ROS) and depress ER stress-mediated NOD activation. Pretreatment with Troxerutin (5 and 10 μM) causes a decrease in the number of cells in the sub G1 phase, indicative of cell death. In the control and Troxerutin-only-treated cells, 3.58±0.15 and 0.89±0.11% are 2′7′-dichlorofluorescein (DCF)-positive (P<0.05), whereas treatment with H2O2 alone increases the level of ROS to 46.36±2.33%. The cells pretreated with Troxerutin are 19.92±1.95% DCF-positive following H2O2 treatment, indicating that Troxerutin reduces the H2O2-induced production of ROS in the HDP cells. Oral administration of Troxerutin notably inhibits those liver injuries in HFD-treated mice, restores glucose intolerance and insulin signaling, and diminishes hepatic gluconeogenesis in HFD-treated mice. Troxerutin remarkably inhibits the nuclear translocation of NF-κB p65, as well as the expressions of its target genes, in the livers of HFD-treated mice. Troxerutin also depresses endoplasmic reticulum (ER) stress-mediated Nucleotide oligomerization domain (NOD) activation in HFD-treated mouse livers.
| Molecular Weight | 742.68 |
| Formula | C33H42O19 |
| CAS Number | 7085-55-4 |
| Solubility (25°C) | Soluble in Water Soluble in DMSO |
| Storage | -20°C, sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related NLR Products |
|---|
| Selnoflast
Selnoflast is an orally effective inhibitor of NLRP3 for studies related to systemic inflammation. |
| (±)11(12)-EET
(±)11(12)-EET is an NLRP3 inflammatory vesicle inhibitor that can be used in studies related to anti-inflammation, neovascularization, and cardioprotection. |
| Antcin A
Antcin A is an NLRP3 inhibitor that inhibits the assembly and activation of NLRP3 inflammatory vesicles. In addition, Antcin A inhibits pyroptosis of Kupffer cells and has hepatoprotective activity.Antcin A can be used in inflammation-related studies. |
| ADS032
ADS032 is a dual inhibitor of NLRP1 and NLRP3 that rapidly, reversibly and stably inhibits inflammasome formation and reduces NLPR1 and NLRP3 activation of human-derived macrophages and bronchial epithelial cells to secrete and mature IL-1β and TNF-α, and reduces NLRP3-induced ASC speck formation. In addition, ADS032 protects mice from the deadly influenza A virus, reduces lung inflammation and improves survival. |
| Emlenoflast sodium
Emlenoflast sodium is a sulfonylurea and a potent and selective inhibitor of NLRP3 inflammatory vesicles with an IC50 value of less than 100 nM.Emlenoflast sodium can be used in the study of inflammatory diseases. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
